AI assistant
AVACTA GROUP PLC — AGM Information 2019
Jan 21, 2019
7507_dva_2019-01-21_0f6f9040-19f8-42f4-8267-7298c4613118.html
AGM Information
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 6792N
Avacta Group PLC
21 January 2019
21 January 2019
Avacta Group plc
("Avacta", the "Group" or the "Company")
Result of Annual General Meeting
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents announces that at the Annual General Meeting held earlier today, all resolutions were duly passed.
The full text of each resolution is set out in the Notice of Annual General Meeting, included in the 2018 Annual Report, which is available on the Company's website www.avacta.com.
- Ends -
For further information from Avacta Group plc, please contact:
| Avacta Group plc Alastair Smith, Chief Executive Officer Tony Gardiner, Chief Financial Officer |
Tel: +44 (0) 844 414 0452 https://www.avacta.com |
| finnCap Ltd Geoff Nash / Giles Rolls - Nominated Adviser Tim Redfern - ECM WG Partners Nigel Birks / Nigel Barnes David Wilson / Claes Spang |
Tel: +44 (0) 207 220 0500 www.finncap.com Tel: +44 (0) 203 705 9318 Tel: +44 (0) 203 705 9217 www.wgpartners.co.uk |
| Turner Pope Investments James Pope Zyme Communications (Trade and Regional Media) Katie Odgaard Yellow Jersey (Financial Media and IR) Sarah Hollins Harriet Jackson |
Tel: 020 3621 4120 [email protected] Tel: +44 (0)7787 502 947 [email protected] Tel: +44 (0)7764 947137 Tel: +44 (0)7544 275882 [email protected] |
About Avacta Group plc (www.avacta.com)
Avacta's principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.
Antibodies dominate markets worth in excess of $100bn despite their shortcomings. Affimer® technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer® technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.
Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer® reagents through licensing to developers of life sciences research tools and diagnostics.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
END
RAGPGUPWGUPBGAG